FUJIY - Fujifilm begins U.S. study of its drug candidate FF-10832 in combination with Keytruda

Japan's Fujifilm (OTCPK:FUJIY) on Tuesday said it had begun a U.S. phase 2a study of its drug candidate FF-10832 in combination with Merck's (MRK) Keytruda for the treatment of various cancers. The mid-stage trial's primary aim is to establish the safety and tolerability of FF-10832 in combination with Keytruda in patients with advanced solid tumors. The trial's primary aim is to also evaluate the combination's primary efficacy in non-small cell lung cancer and urothelial cancer patients who have progressed after standard therapy, including immune checkpoint inhibitor therapy. The trial will enroll up to 100 patients in the indications of non-small cell lung cancer and urothelial cancer into a monotherapy arm and a Keytruda-combination arm. Fujifilm's FF-10832, which is intravenously administered, consists of artificially constructed lipid vesicles called liposomes that encapsulate anti-cancer agent gemcitabine. U.S.-listed shares of FUJIY +0.7% to $54.60 in morning trade, while MRK stock -1.4% to $91.75.

For further details see:

Fujifilm begins U.S. study of its drug candidate FF-10832 in combination with Keytruda